DUBLIN--(BUSINESS WIRE)--The "PD-1 x VEGF and PD-L1 x VEGF Bispecific ... clinical profile and molecular structure of drug candidates and business deals from an industry perspective as of February ...
Findings on golidocitinib for patients with non-small cell lung cancer whose disease has progressed on anti-PD-1 therapy will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback